blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1778637

EP1778637 - FKBP-binding composition and pharmaceutical use thereof [Right-click to bookmark this link]
Former [2007/18]FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF
[2011/33]
StatusNo opposition filed within time limit
Status updated on  28.12.2012
Database last updated on 19.07.2024
Most recent event   Tooltip14.06.2019Change - lapse in a contracting state
State(s) deleted from list of lapses: TR		published on 17.07.2019  [2019/29]
Applicant(s)For all designated states
Aventis Pharmaceuticals Inc.
300 Somerset Corporate Boulevard
Bridgewater, New Jersey 08807 / US
[2007/18]
Inventor(s)01 / KOSLEY, JR., Raymond, W.
659 Cedarbrook Road
Bridgewater, NJ 08807 / US
02 / BARON, Bruce
763 Boulevard
Westfield, NJ 07090 / US
03 / JIMONET, Patrick
13 avenue de Normandie
F-78450 Villepreux / FR
04 / JURCAK, John, G.
2431 13th Street
Bethlehem, Pennsylvania 18020 / US
05 / SHIMSHOCK, Stephen, J.
13 Banor Drive
Hillsborough, New Jersey 08844 / US
06 / ZHAO, Xu-Yang
7 Decker Lane
Bridgewater, New Jersey 08807 / US
07 / SHER, Rosy
13 Kelly Court
Bridgewater, New Jersey 08807 / US
08 / MUELLER, Paul, J.
1015 Washington Street, Apt 52
Hoboken, New Jersey 07030 / US
09 / BEALL, Jennifer
712 Forrest Avenue
Geneva, Illinois 60134 / US
10 / BARRAGUE, Matthieu
100 Manhattan Avenue
Apt. 2303
Union City, New Jersey 07030 / US
11 / GUILES, Joseph, W.
714 Skywalker Place
Lafayette, CO 80026 / US
 [2012/08]
Former [2007/44]01 / KOSLEY, JR., Raymond, W.
659 Cedarbrook Road
Bridgewater, NJ 08807 / US
02 / BARON, Bruce
763 Boulevard
Westfield, NJ 07090 / US
03 / JIMONET, Patrick
13 avenue de Normandie
F-78450 Villepreux / FR
04 / JURCAK, John, G.
2431 13th Street
Bethlehem, Pennsylvania 18020 / US
05 / SHIMSHOCK, Stephen, J.
13 Banor Drive
Hillsborough, New Jersey 08844 / US
06 / ZHAO, Xu-Yang
7 Decker Lane
Bridgewater, New Jersey 08807 / US
07 / SHER, Rosy
13 Kelly Court
Bridgewater, New Jersey 08807 / US
08 / MUELLER, Paul, J.
1015 Washington Street, Apt 52
Hoboken, New Jersey 07030 / US
09 / BEALL, Jennifer
712 Forrest Avenue
Geneva, Illinois 60134 / US
10 / BARRAGUE, Matthieu
100 Manhattan Avenue, Apt. 2303
Union City, New Jersey 07030 / US
11 / GUILES, Joseph, W.
714 Skywalker Place
Lafayette, CO 80026 / US
Former [2007/18]01 / KOSLEY, JR., Raymond, W.
659 Cedarbrook Road
Bridgewater, NJ 08807 / US
02 / BARON, Bruce
763 Boulevard
Westfield, NJ 07090 / US
03 / JIMONET, Patrick
13 avenue de Normandie
F-78450 Villepreux / FR
04 / JURCAK, John, G.
2431 13th Street
Bethlehem, Pennsylvania 18020 / US
05 / SHIMSHOCK, Stephen, J.
13 Banor Drive
Hillsborough, New Jersey 08844 / US
06 / ZHAO, Xu-Yang
7 Decker Lane
Bridgewater, New Jersey 08807 / US
07 / SHER, Rosy
13 Kelly Court
Bridgewater, New Jersey 08807 / US
08 / MUELLER, Paul, J.
1045 Bloomfield St., Apt. 4
Hoboken, New Jersey 07030 / US
09 / BEALL, Jennifer
712 Forrest Avenue
Geneva, Illinois 60134 / US
10 / BARRAGUE, Matthieu
100 Manhattan Avenue, Apt. 2303
Union City, New Jersey 07030 / US
11 / GUILES, Joseph, W.
714 Skywalker Place
Lafayette, CO 80026 / US
Representative(s)Le Pennec, Magali
Aventis Pharma S.A.
Direction des Brevets
Tri LEO/144
20 Avenue Raymond Aron
92165 Antony Cedex / FR
[N/P]
Former [2012/08]Le Pennec, Magali
Aventis Pharma S.A. Direction des Brevets Tri LEO/144 20 Avenue Raymond Aron
92165 Antony Cedex / FR
Former [2008/30]Le Pennec, Magali
Aventis Pharma S.A. Direction des Brevets Tri LEO/144 20 Avenue Raymond Aron
92165 Antony Cedex / FR
Former [2007/18]Le Pennec, Magali
Aventis Pharma S.A. Direction des Brevets, Tri LEO/144 20, avenue Raymond Aron
92165 Antony Cedex / FR
Application number, filing date05763770.424.06.2005
[2007/18]
WO2005US22360
Priority number, dateUS20040583740P29.06.2004         Original published format: US 583740 P
US20040624946P04.11.2004         Original published format: US 624946 P
[2007/18]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006012256
Date:02.02.2006
Language:EN
[2006/05]
Type: A2 Application without search report 
No.:EP1778637
Date:02.05.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 02.02.2006 takes the place of the publication of the European patent application.
[2007/18]
Type: B1 Patent specification 
No.:EP1778637
Date:22.02.2012
Language:EN
[2012/08]
Search report(s)International search report - published on:EP27.04.2006
ClassificationIPC:C07D211/96, C07D401/12, C07D405/12, C07D409/14, A61K31/445, A61K31/453, A61K31/454, A61K31/4545, A61P25/00, A61P25/28
[2007/18]
CPC:
C07D409/14 (EP); A61P25/00 (EP); A61P25/16 (EP);
A61P25/28 (EP); A61P37/02 (EP); A61P9/00 (EP);
C07D211/96 (EP); C07D401/12 (EP); C07D405/12 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/18]
Extension statesAL29.01.2007
BA29.01.2007
HR29.01.2007
LV29.01.2007
MK29.01.2007
YU29.01.2007
TitleGerman:FKBP bindende Zusammensetzung und deren pharmazeutische Verwendung[2011/33]
English:FKBP-binding composition and pharmaceutical use thereof[2011/33]
French:Composition de liaison aux protéines FKBP et utilisation pharmaceutique associée[2011/33]
Former [2007/18]FKBP-BINDENDE ZUSAMMENSETZUNG UND DEREN PHARMAZEUTISCHE VERWENDUNG
Former [2007/18]FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF
Former [2007/18]COMPOSITION DE LIAISON AUX PROTEINES FKBP ET UTILISATION PHARMACEUTIQUE ASSOCIEE
Entry into regional phase29.01.2007National basic fee paid 
29.01.2007Designation fee(s) paid 
29.01.2007Examination fee paid 
Examination procedure29.01.2007Examination requested  [2007/18]
29.09.2009Despatch of a communication from the examining division (Time limit: M04)
05.02.2010Reply to a communication from the examining division
05.09.2011Communication of intention to grant the patent
09.01.2012Fee for grant paid
09.01.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.09.2009
Opposition(s)23.11.2012No opposition filed within time limit [2013/05]
Fees paidRenewal fee
27.06.2007Renewal fee patent year 03
28.03.2008Renewal fee patent year 04
16.06.2009Renewal fee patent year 05
11.06.2010Renewal fee patent year 06
13.06.2011Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.06.2005
CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
SK22.02.2012
BG22.05.2012
IS22.06.2012
LU24.06.2012
MC30.06.2012
[2019/29]
Former [2014/34]HU24.06.2005
CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
SK22.02.2012
BG22.05.2012
IS22.06.2012
LU24.06.2012
TR24.06.2012
MC30.06.2012
Former [2014/27]CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
SK22.02.2012
BG22.05.2012
IS22.06.2012
LU24.06.2012
TR24.06.2012
MC30.06.2012
Former [2014/25]CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
SK22.02.2012
BG22.05.2012
IS22.06.2012
TR24.06.2012
MC30.06.2012
Former [2013/33]CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
SK22.02.2012
BG22.05.2012
IS22.06.2012
MC30.06.2012
Former [2013/08]CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
SK22.02.2012
IS22.06.2012
MC30.06.2012
Former [2012/50]CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
SK22.02.2012
IS22.06.2012
Former [2012/49]CY22.02.2012
CZ22.02.2012
EE22.02.2012
LT22.02.2012
PL22.02.2012
RO22.02.2012
SI22.02.2012
IS22.06.2012
Former [2012/48]CY22.02.2012
EE22.02.2012
LT22.02.2012
IS22.06.2012
Former [2012/41]CY22.02.2012
LT22.02.2012
IS22.06.2012
Former [2012/34]LT22.02.2012
IS22.06.2012
Former [2012/33]LT22.02.2012
Cited inInternational search[AD]WO9640140  (GUILFORD PHARM INC [US], et al);
 [AD]WO9716190  (GUILFORD PHARM INC [US]);
 [AD]US5696135  (STEINER JOSEPH P [US], et al);
 [A]WO9853814  (MERCK & CO INC [US], et al) [A] 1,6 * page 1, line 5 - line 21 * * page 16, line 11 - line 14 ** claims 1,5,15,18-20 *;
 [A]US6268384  (NOVAK PERRY M [US], et al) [A] 1-4,6-9,11,17-19,22 * column 5, line 66 - column 7, line 40; examples 1,3; claims 1,10 *;
 [AD]US2002052372  (STEINER JOSEPH P [US], et al) [AD] 1,6,11,21,22 * page 18, examples no. 54 and 55;;; claims 1,10 *;
 [AD]US2002052410  (STEINER JOSEPH P [US], et al) [AD] 1,6,11,21,22 * examples 77-86; claims 1,11-14 *;
 [X]  - I. O. DONKOR ET AL, "Peptidyl Aldehyde Inhibitors of Calpain Incorporating P2-Proline Mimetics", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2003), vol. 13, no. 5, pages 783 - 784, XP002362047 [X] 1,2 * page 784, scheme 1, compound 3d *

DOI:   http://dx.doi.org/10.1016/S0960-894X(03)00021-0
by applicantUS6268384
 US2002052410
 US2002052372
    - DONKOR IA ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2003), vol. 13, no. 5, pages 783 - 784
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.